Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or Chronic Lymphocytic Leukemia

NCT01944943 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

31

Enrollment

OTHER

Sponsor class

Stopped lack of efficacy

Conditions

Diffuse Large B-cell Lymphoma
Indolent Non-hodgkin Lymphoma
Primary Central Nervous System Lymphoma
Chronic Lymphocytic Leukemia

Interventions

DRUG: Vismodegib

Sponsor

The Lymphoma Academic Research Organisation

Collaborators

[object Object]